Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibritumomab tiuxetan - Acrotech Biopharma /Biogen

Drug Profile

Ibritumomab tiuxetan - Acrotech Biopharma /Biogen

Alternative Names: 111In-ibritumomab tiuxetan; BAY86-5128; IDEC-129; IDEC-In2B8; IDEC-Y2B8; Indium-111 Ibritumomab tiuxetan; Monoclonal antibody IDEC-Y2B8; SH-L-749; Yttrium-90 ibritumomab tiuxetan; ZEVALIN; Zevalin; Zevamab

Latest Information Update: 07 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Acrotech Biopharma; Bayer Yakuhin; Biogen; CASI Pharmaceuticals; Dana-Farber Cancer Institute; Schering Korea; Tufts-New England Medical Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Discontinued Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma

Most Recent Events

  • 06 Mar 2019 Spectrum Pharmaceuticals completes sale of ibritumomab tiuxetan to Acrotech Biopharma
  • 19 Feb 2019 The National Medical Products Administration (NMPA) of China approves a clinical trial application for the conduction of a confirmatory clinical trial of ibritumomab tiuxetan in Non-Hodgkin's lymphoma (Second-line therapy or greater)
  • 11 Sep 2018 Product re-launched for indolent Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) during before September 2018 in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top